A Phase 1 interventional study of Vedolizumab and Placebo in Inflammatory Bowel Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-21.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Inflammatory Bowel Diseases by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Inflammatory Bowel Diseases · Takeda.
Among the 24 studies in Inflammatory Bowel Diseases by Takeda, this one is the only one that started in 2011, is the only one in phase 1, and was the 2nd registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →1 of the 24 studies in Inflammatory Bowel Diseases by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2011.
This study's enrollment of 127 is above the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 127 across the 3 interventional studies, 335 across the 21 observational. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
1 of the studies in Inflammatory Bowel Diseases by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428345TakedaA Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Inflammatory Bowel Diseases by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine the rates of seroconversion to a hepatitis B vaccine series after a single 750 mg intravenous (IV) dose of vedolizumab or placebo. Secondary objectives are to determine the rates of seroconversion to an oral cholera vaccine series, assess change in anti-hepatitis B surface antibodies and assess the safety and tolerability of a single 750-mg IV dose of vedolizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
Drug: Vedolizumab · Biological: Hepatitis B vaccine · Biological: Oral cholera vaccine
Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
Drug: Placebo · Biological: Hepatitis B vaccine · Biological: Oral cholera vaccine
Vedolizumab for intravenous infusion
Also known as: Entyvio, MLN0002, MLN02, LDP-02
Placebo intravenous infusion
Also known as: HBVAXPRO
Also known as: Dukoral
Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74
Immune response was defined as hepatitis B surface antibody (anti-HBs) ≥ 10 IU/L.
Time frame: Day 74
Percentage of Participants With an Immune Response to Oral Cholera Vaccine
A positive immune response was defined as an increase of greater than 4-fold over the Baseline immunoglobulin M (IgM), IgG, or IgA anticholera antibodies.
Time frame: Baseline and Day 74
Anti-Hepatitis B Surface Antibody Over Time
Time frame: Baseline and Days 18, 32, 60 and 74
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment. Serious adverse event (SAE) meant any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. Relationship of each AE to study drug was determined by the Investigator.
Time frame: From the first dose of study medication through Day 127
Participants took part in the study at one investigative site in the United Kingdom from 13 September 2011 to 13 July 2012.
| Milestone | Vedolizumab 750 mg | Placebo |
|---|---|---|
| Started | 64 | 63 |
| Completed | 63 | 62 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
Immune response was defined as hepatitis B surface antibody (anti-HBs) ≥ 10 IU/L.
| percentage of participants | Vedolizumab 750 mg | Placebo |
|---|---|---|
| Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74 | 88.5 (80.5 to 96.5) | 90.3 (83.0 to 97.7) |
A positive immune response was defined as an increase of greater than 4-fold over the Baseline immunoglobulin M (IgM), IgG, or IgA anticholera antibodies.
| percentage of participants | Vedolizumab 750 mg | Placebo |
|---|---|---|
| Percentage of Participants With an Immune Response to Oral Cholera Vaccine | 82.5 (73.2 to 91.9) | 96.8 (92.4 to 100.0) |
| IU/L | Vedolizumab 750 mg | Placebo |
|---|---|---|
| Baseline (n=24, 31) | 1.2 ± 51.9 | 1.0 ± 12.5 |
| Day 18 (n=39, 40) | 2.5 ± 501.0 | 1.3 ± 73.5 |
| Day 32 (n=37, 41) | 2.3 ± 472.8 | 1.6 ± 99.9 |
| Day 60 (n=58, 59) | 16.3 ± 501.3 | 15.2 ± 365.8 |
| Day 74 (n=59, 62) | 129.6 ± 359.3 | 114.4 ± 539.6 |
An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment. Serious adverse event (SAE) meant any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. Relationship of each AE to study drug was determined by the Investigator.
| participants | Vedolizumab 750 mg | Placebo |
|---|---|---|
| Any adverse event | 41 | 50 |
| Drug-related adverse event | 22 | 22 |
| Adverse event resulting in study discontinuation | 0 | 1 |
| Serious adverse event | 0 | 1 |
| Serious infection adverse events | 0 | 0 |
| Drug-related serious adverse event | 0 | 0 |
| Serious adverse event resulting in discontinuation | 0 | 0 |
| Deaths | 0 | 0 |
Collected over From the first dose of study medication through Day 127.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vedolizumab 750 mg | — | 0/64 (0%) | 24/64 (37.5%) |
| Placebo | — | 1/63 (1.6%) | 25/63 (39.7%) |
| Event | Vedolizumab 750 mg | Placebo |
|---|---|---|
| Spontaneous abortionPregnancy, puerperium and perinatal conditions | 0/64 | 1/63 |
| Event | Vedolizumab 750 mg | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 12/64 | 8/63 |
| Viral upper respiratory tract infectionInfections and infestations | 8/64 | 8/63 |
| GastroenteritisInfections and infestations | 2/64 | 5/63 |
| FatigueGeneral disorders | 1/64 | 4/63 |
| Upper respiratory tract infectionInfections and infestations | 4/64 | 3/63 |
| NauseaGastrointestinal disorders | 4/64 | 0/63 |
| Age, Continuous(years) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| Mean | 27.7 ± 5.64 | 27.3 ± 5.33 | 27.5 ± 5.47 |
| Sex: Female, Male(Participants) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| Female | 20 | 20 | 40 |
| Male | 44 | 43 | 87 |
| Race/Ethnicity, Customized(participants) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| White | 62 | 56 | 118 |
| Black | 1 | 1 | 2 |
| Asian | 1 | 2 | 3 |
| Other | 0 | 4 | 4 |
| Race/Ethnicity, Customized(participants) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 64 | 62 | 126 |
| Region of Enrollment(participants) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| United Kingdom | 64 | 63 | 127 |
| Height(cm) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| Mean | 173.4 ± 8.89 | 173.1 ± 7.94 | 173.3 ± 8.40 |
| Weight(kg) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| Mean | 75.0 ± 13.48 | 76.2 ± 11.53 | 75.6 ± 12.51 |
| Body Mass Index (BMI)(kg/m^2) | Vedolizumab 750 mg | Placebo | Total |
|---|---|---|---|
| Mean | 24.8 ± 3.34 | 25.4 ± 2.71 | 25.1 ± 3.04 |
The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →